ARL3: A Potential Drug Target for Cancer and Genetic Disorders

Target Name: ARL3

NCBI ID: G403

ARL3: A Potential Drug Target for Cancer and Genetic Disorders

ARL3 (RNA-Protein Ligase III) is a protein that is expressed in various cell types, including neurons, muscle cells, and immune cells. It is a key enzyme in the process of RNA breakage, which is the breakdown of RNA into smaller pieces called ribonucleotides. This process is important for the proper functioning of RNA and for the regulation of gene expression.

One of the functions of ARL3 is to catalyze the breakdown of RNA into the 5鈥?-end cap structure. The cap structure is made up of a polynucleotide consisting of uracil (U) and cytosine (C). It is a stable structure of RNA that protects RNA from degradation and nuclease degradation.

ARL3 also plays a role in the regulation of gene expression by targeted cleavage of pre-mRNA by RNA-protein ligase III (RPL3), which is a protein-RNA ligase that recognizes specific sequences in the pre-mRNA sequence and cuts the RNA at specific sites. This cleavage allows for specific editing of the pre-mRNA byRNA-protein ligase III, which is a potential drug target for various diseases.

In addition to its role in RNA breakage and gene expression regulation, ARL3 is also a potential biomarker for certain diseases. For example, ARL3 has been shown to be elevated in the blood of individuals with certain forms of cancer, such as lung cancer and breast cancer. This suggests that ARL3 may be a useful target for cancer therapies that target RNA-based processes.

Furthermore, ARL3 is also a potential drug target for treating genetic disorders such as hemophilia. The defect in ARL3 has been shown to contribute to the development of hemophilia in certain individuals. Therefore, ARL3 may be a promising target for developing new treatments for hemophilia.

In conclusion, ARL3 is a protein that plays a critical role in RNA breakage and gene expression regulation. Its function as a RNA-protein ligase III makes it a potential drug target for various diseases. The elevated expression of ARL3 in the blood of individuals with certain forms of cancer and its potential as a biomarker for certain diseases make it an attractive target for further research.

Protein Name: ADP Ribosylation Factor Like GTPase 3

Functions: Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP) (PubMed:16525022, PubMed:18588884). Required for normal cytokinesis and cilia signaling (PubMed:22085962). Requires assistance from GTPase-activating proteins (GAPs) like RP2 and PDE6D, in order to cycle between inactive GDP-bound and active GTP-bound forms. Required for targeting proteins to the cilium, including myristoylated NPHP3 and prenylated INPP5E (PubMed:30269812). Targets NPHP3 to the ciliary membrane by releasing myristoylated NPHP3 from UNC119B cargo adapter into the cilium (PubMed:22085962). Required for PKD1:PKD2 complex targeting from the trans-Golgi network to the cilium (By similarity)

More Common Targets